Business Wire

CA-MFA

16.11.2021 15:03:14 CET | Business Wire | Press release

Share
MFA Launches Network Identifier Program for Enterprises to Deploy Their Own Private Network

MFA , an international organization championing the global industry adoption of private networks based upon 3GPP technologies, today announced its Network Identifier Program for enterprises. Enterprises now have access to the MFA’s unique global PLMN ID that they can use when deploying their own private network to ensure that only authorized devices connect to their network. The program reduces complexity and streamlines the network development process for enterprises by eliminating the need for them to separately apply for their own PLMN ID.

“Our mission is to make it as easy as possible for enterprises to quickly deploy their own private network and realize the benefits of greater control over their network, enhanced on-premise data security, and predictable performance,” said Mazen Chmaytelli, president, MFA. “MFA was awarded a unique global PLMN ID by the ITU, and we are creating this new program to ensure all industry verticals have ready access to a PLMN ID that will support their digitalization journey.”

Enterprises and industry verticals including maritime, manufacturing, warehouses, utilities, and venues can select a Private Network ID package or a Neutral Host Network (NHN) ID package that will provide them with all the items they need to deploy a neutral host or private network. For large deployments, enterprises will be able to add-on IDs to meet their requirements for coverage and capacity.

“With access to the global PLMN ID from MFA, network suppliers or operators will have the necessary identifiers to create unique and distinguishable private networks, streamlining the deployment process for their enterprise customers – anywhere in the world they are located,” said Asimakis Kokkos, MFA Technical Specification Group Chair and Head of Technology Ecosystems, Nokia Enterprise Solutions.

New Private Network Subscriber category created to jumpstart deployment
MFA has also created a new Private Network Subscriber category that will grant enterprises one complimentary Private Network ID package that they can use immediately to deploy their own 5G private network in locally licensed spectrum or MulteFire®/4G private network in unlicensed spectrum today.

“For a one-time fee, Private Network Subscribers gain access to a Private Network ID package that is evergreen and does not need to be renewed,” added Chmaytelli. “Our members also will receive complimentary packages that will meet their deployment requirements. The MFA wants to help seed as many private networks as possible, and we’re excited to bring this important program to the entire industry.”

To further enable private network deployments, MFA, a 3GPP Market Representation Partner (MRP), previously announced that it is also developing Uni5G™ Technology Blueprints. These blueprints will provide enterprises with practical guidance on implementing the key features from the 3GPP 5G standards that are relevant to their specific deployment. The first blueprints will be finalized in December 2021.

The Network Identifier program is administered by the MFA Certificate Authority and is available today to MFA members and non-members. For companies interested in joining the program, visit www.mfa-tech.org .

Resources:

About MFA
MFA is an international organization that is championing the global industry adoption of private networks using MFA-defined MulteFire specifications for LTE and Uni5G Technology Blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye